TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05767190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: During the intervention, the trained-nurse will provide a motivational interviewing-based intervention consisting of one session divided into two parts: educational (the concepts of sleep apnea and the symptoms, and the CPAP treatment will be focused on) and training activity (using MI not directly advocate for behavioral change (i.e., use CPAP as prescribed), but asks key questions to help the patient explore conflicting feelings about the change, weighs the positive consequences and negatives of this change, and allows the patient to realize the discrepancy between current risk behavior (i.e. not using CPAP as directed) and the patient's self-identified goals. The intervention will be tailored on the patient's stage of change based on Prochaska and DiClemente transtheoretical model (1982), in fact, the nurse will use MI not only at the beginning of therapy but also in every contact with the patient throughout the treatment (subsequent follow-up visits, phone calls, etc.).
Study: NCT06014099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Long peripheral venous catheters for blood collection
Description: used LPC for blood collection

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Midline catheter for blood collection
Description: used MCs for blood collection

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SPCs for blood collection
Description: used SPCs for blood collection
Study: NCT06583408

Intervention type: OTHER
Intervention: Automated Self-Administered 24-hour Dietary Assessment Tool (ASA24)
Description: Subjects will complete the ASA food diary for 2 weekdays and 1 weekend day

Intervention type: OTHER
Intervention: REVEAL Questionnaire
Description: Subjects will complete the REVEAL questionnaire form. This form includes questions about current and past medical history, including reproductive history, lifestyle specifics, and assessment of current health status.
Study: NCT06583577

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Ostomy simulator
Description: The ostomy simulator is 3D printed model created in collaboration with Earl E. Bakken Medical Devices Center at the University of Minnesota. The anatomically accurate model is created by analyzing de-identified segmental imaging after bowel diversion surgeries. The Stratasys J750 Polyjet 3D Printer is utilized to create the simulator using usual synthetic material.
Study: NCT06584162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab Injection
Description: Based on therapeutic drug monitoring, patients could be de-escalated based on a pharmacokinetic model:~Dosing interval Trough Target 20 mg/L~Adjust dosing interval to:~2 weeks \< 33 mg/L 2 weeks 2 weeks 33 - 46 mg/L 3 weeks 2 weeks ≥ 46 mg/L 4 weeks 3 weeks \< 20 mg/L 2 weeks 3 weeks 20 - 29 mg/L 3 weeks 3 weeks ≥ 29 mg/L 4 weeks 4 weeks \< 13 mg/L 2 weeks 4 weeks 13 - 20 mg/L 3 weeks Version number: 6.1, 24-06-2024 22 of 44 4 weeks ≥ 20 mg/L 4 week
Study: NCT05455931

Intervention type: DRUG
Intervention: Poteligeo
Description: Poteligeo treatment will be used as prescribed by the Investigator in accordance with the terms of the reimbursed indication within the relevant country. The assignment of the patient to a particular therapeutic strategy falls within current practice and the prescription of Poteligeo is clearly separated from the decision to include the patient in the study.
Study: NCT06548932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR33 Injection
Description: A single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR101 Injection
Description: A single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single dose
Study: NCT06429774

Intervention type: OTHER
Intervention: Neurological function
Description: Neurological function will be examined using Glasgow Coma Scale (GCS) and Extended Glasgow Outcome Scale (GOSE).The GOSE was created as an advancement from the original GOS. The GOSE score categorizes the prognosis of patients with traumatic brain injury into eight categories.The 8 categories are: Dead, Vegetative State, Lower Severe Disability, Upper Severe Disability, Lower Moderate Disability, Upper Moderate Disability, Lower Good Recovery, and Upper Good Recovery.

Intervention type: OTHER
Intervention: Mental State, cognitive function, and life quality assessment
Description: Mental State, cognitive function, and life quality will be examined using the Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9(PHQ-9), Rivermead post-concussion symptoms questionnaire(RPQ), PTSD Checklist-5 Version(PCL-5)，Six-Item Screener（SIS） and 12-Item Short-Form Health Survey version 2(SF-12v2).

Intervention type: OTHER
Intervention: Peripheral blood test
Description: Collect peripheral blood samples from patients.

Intervention type: OTHER
Intervention: Hematoma test
Description: Collect hematoma fluid, dura mater, and hematoma outer membrane samples from patients.
Study: NCT05886712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Naloxone

Intervention type: OTHER
Group type: OTHER
Intervention: Usual intervention
Description: usual administered drug for overdose
Study: NCT05860465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH4336 Tablets
Description: SPH4336 Tablets ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SPH4336 Tablets Placebo
Description: SPH4336 Tablets Placebo ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion
Study: NCT05460468

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve a variety of cognitive conditions, and to probe the dynamics of normal brain function.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve a variety of cognitive conditions, and to probe the dynamics of normal brain function.
Study: NCT05138679

Intervention type: PROCEDURE
Intervention: Revascularization
Description: Endovascular or surgical restoration of arterial blood flow.

Intervention type: PROCEDURE
Intervention: Primary major amputation
Description: Primary below- or above knee major amputation without prior revascularization.

Intervention type: OTHER
Intervention: Best medical treatment
Description: Conservative treatment of acute lower limb ischemia - without prior revascularization.
Study: NCT05460468

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve a variety of cognitive conditions, and to probe the dynamics of normal brain function.
Study: NCT05098145

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FCR001
Description: Enriched hematopoietic stem cell infusion
Study: NCT04391803

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pipeline™ Flex Embolization Device with Shield Technology™
Description: The Pipeline™ Flex Embolization Device with Shield Technology™ is intended for endovascular treatment of adults with intracranial acutely ruptured aneurysms not amenable to clipping and coiling.
Study: NCT06576219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Music Therapy
Description: My Life Is Music group therapy model
Study: NCT06429800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATA3219
Description: ATA3219 is an allogeneic chimeric antigen receptor (CAR) T-cell therapy containing a second generation CD19 CAR construct in Epstein Barr virus (EBV) T cells, administered intravenously on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATA3219
Description: ATA3219 is an allogeneic chimeric antigen receptor (CAR) T-cell therapy containing a second generation CD19 CAR construct in Epstein Barr virus (EBV) T cells, administered intravenously on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATA3219
Description: ATA3219 is an allogeneic chimeric antigen receptor (CAR) T-cell therapy containing a second generation CD19 CAR construct in Epstein Barr virus (EBV) T cells, administered intravenously on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATA3219
Description: ATA3219 is an allogeneic chimeric antigen receptor (CAR) T-cell therapy containing a second generation CD19 CAR construct in Epstein Barr virus (EBV) T cells, administered intravenously on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATA3219
Description: ATA3219 is an allogeneic chimeric antigen receptor (CAR) T-cell therapy containing a second generation CD19 CAR construct in Epstein Barr virus (EBV) T cells, administered intravenously on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATA3219
Description: ATA3219 is an allogeneic chimeric antigen receptor (CAR) T-cell therapy containing a second generation CD19 CAR construct in Epstein Barr virus (EBV) T cells, administered intravenously on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATA3219
Description: ATA3219 is an allogeneic chimeric antigen receptor (CAR) T-cell therapy containing a second generation CD19 CAR construct in Epstein Barr virus (EBV) T cells, administered intravenously on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATA3219
Description: ATA3219 is an allogeneic chimeric antigen receptor (CAR) T-cell therapy containing a second generation CD19 CAR construct in Epstein Barr virus (EBV) T cells, administered intravenously on Day 1.
Study: NCT04828005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene hydrochloride
Description: 3mg Nasal spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone hydrochloride
Description: 4mg Nasal Spray
Study: NCT05207683

Intervention type: OTHER
Intervention: echocardiography
Description: All the patients will be subjected to thorough medical history and clinical examination and the results of the previous investigations will be collected aiming for reaching the diagnosis of the etiology of pulmonary hypertension. ct pulmonary angiography and then right heart catheterization will be done in case of undiagnosed etiology.
Study: NCT04684953

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Throid autotransplantation
Description: Operative

Intervention type: DRUG
Group type: OTHER
Intervention: Hormone
Description: thyroid hormone replacement therapy
Study: NCT05885802

Intervention type: OTHER
Intervention: No specific intervention other than routine anesthesia protocol
Description: No specific intervention other than routine anesthesia protocol
Study: NCT05215158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: to compare perineural (peribulbar) dexmedetomidine versus intravenous (I.V.) dexmedetomidine when used as an adjuvant with local anesthesia in adult strabismus surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: to compare perineural (peribulbar) dexmedetomidine versus intravenous (I.V.) dexmedetomidine when used as an adjuvant with local anesthesia in adult strabismus surgery.
Study: NCT05892640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Salt Diet
Description: Low-salt diet (LS diet) according to DASH eating plan, with sodium intake of 1500 mg (3.75 g of salt), within the period of 14 days
Study: NCT05729984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paula exercises
Description: The patients will perform Paula exercises after the cesarean delivery
Study: NCT04937127

Intervention type: BEHAVIORAL
Intervention: I-LEARN training
Description: Training of psycho-behavorial disorders care in neurodegenerative diseases: including a theoretical part in e-learning and a practical part

Intervention type: OTHER
Intervention: usual care
Description: usual care

Intervention type: OTHER
Intervention: usual care
Description: usual care
Study: NCT05899127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 1.5mg/kg induction，1.5 mg/kg/h maintenance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9%NaCl
Description: 2mg/kg induction，1.5 mg/kg/h maintenance
Study: NCT05729984

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gum chewing
Description: The patients will be given chewing gum and will be asked to chew it after the cesarean delivery
Study: NCT04969731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immuncell-LC
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV
Study: NCT06178003

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tpdelansbsalbac
Description: Tpdelansbsalbac,which is Knockdown of ansB, a gene that expresses L-mentholase secreted into the extracellular region, on the basis of the genetic background of bacterium VNP20009, and construction of an ansB gene-deficient mutant strain, ΔansB.
Study: NCT05792111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trigger point injection (lidocaine)
Description: trigger point injection will be added to the gluteus medius and minimus muscles in addition to caudal epidural steroid injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caudal epidural Group (bupivacaine + triamcinolone + NaCl)
Description: It will be advanced towards the sacral hiatus and local anesthesia of the skin and subcutaneous tissue will be provided with 2% lidocaine. The caudal epidural space will be entered by puncturing the sacrococcygeal ligament with the tip of a 22 G black needle from the appropriate area and taking a pop sensation. It will be confirmed that there is no bleeding or cerebrospinal fluid in this area by applying saline in real-time sonography and after the caudal epidural spread is observed, aspiration is performed. Afterward, a 10 mL volume of bupivacaine 4cc/20mg+ triamcinolone 2cc/80mg+0.09% NaCl 4cc mixture will be administered into the caudal epidural space
Study: NCT06449963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Belief Model Education
Description: Participants in this group will receive a structured training program with the aim of increasing daily water consumption and reducing symptoms of dehydration. The program is based on the principles of the Health Belief Model and includes the following components:~Initial and mid-Program training: Will be conducted by a trained health educator, each lasting 60 minutes. Two weeks after the first training, the same training will be given again for reinforcement purposes.~Session Content: Covers the importance of hydration, strategies to increase water intake (using reminders, setting goals, integrating water-rich foods), and the health benefits of adequate hydration (e.g., improved cognitive function, better physical health).~Training Materials: Booklet prepared for training. Behavioral Strategies: Practical tips for overcoming barriers to drinking more water, such as setting daily water intake goals and using diaries to track progress.
Study: NCT06221722

Intervention type: DIAGNOSTIC_TEST
Intervention: BOLD-fMRI
Description: Blood-Oxygen-Level Dependent Functional Magnetic Resonance Imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: BOLD-fMRI
Description: Blood-Oxygen-Level Dependent Functional Magnetic Resonance Imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: BOLD-fMRI
Description: Blood-Oxygen-Level Dependent Functional Magnetic Resonance Imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: BOLD-fMRI
Description: Blood-Oxygen-Level Dependent Functional Magnetic Resonance Imaging
Study: NCT06065579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Well-Being Promotion Program
Description: the well-being promotion program (Suldo,2016) , an intervention designed to improve subjective well-being. It was postulated that this intervention will eventually assist in managing emotional and behavioural problems among adolescents enrolled in the program.
Study: NCT06221722

Intervention type: DRUG
Intervention: Regular treatment of functional constipation
Description: at least 3 months of continuous regular treatment. This treatment included the utilization of osmotic laxatives, stimulant laxatives, prosecretory agents, and a high-fibre diet.

Intervention type: DRUG
Intervention: Regular treatment of functional constipation
Description: at least 3 months of continuous regular treatment. This treatment included the utilization of osmotic laxatives, stimulant laxatives, prosecretory agents, and a high-fibre diet.

Intervention type: DRUG
Intervention: Regular treatment of functional constipation
Description: at least 3 months of continuous regular treatment. This treatment included the utilization of osmotic laxatives, stimulant laxatives, prosecretory agents, and a high-fibre diet.

Intervention type: DRUG
Intervention: fluoxetine
Description: Fluoxetine oral treatment for 4 weeks.

Intervention type: DRUG
Intervention: fluoxetine
Description: Fluoxetine oral treatment for 4 weeks.
Study: NCT05078268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HRV biofeedback training and self-help CBT-I
Description: Participants will receive a booklet with content related to both self-help CBT-I and HRV biofeedback per week for 6 consecutive weeks. Participants are required to use around 1 hour to read through the content and perform the HRV biofeedback practice for around 20 minutes a day, 5-7 days a week and record their practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help CBT-I only
Description: Participants will receive a booklet with content related to self-help CBT-I only per week for 6 consecutive weeks. Participants are required to use 30 to 40 minutes to read through the content.
Study: NCT06413030

Intervention type: DIAGNOSTIC_TEST
Intervention: 10 Meter Walk Test
Description: Gait Speed Test
Study: NCT05792111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caudal epidural Group (bupivacaine + triamcinolone + NaCl)
Description: It will be advanced towards the sacral hiatus and local anesthesia of the skin and subcutaneous tissue will be provided with 2% lidocaine. The caudal epidural space will be entered by puncturing the sacrococcygeal ligament with the tip of a 22 G black needle from the appropriate area and taking a pop sensation. It will be confirmed that there is no bleeding or cerebrospinal fluid in this area by applying saline in real-time sonography and after the caudal epidural spread is observed, aspiration is performed. Afterward, a 10 mL volume of bupivacaine 4cc/20mg+ triamcinolone 2cc/80mg+0.09% NaCl 4cc mixture will be administered into the caudal epidural space
Study: NCT04945109

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mankai beverage
Description: Recommended background healthy diet with Mankai supplementation after main meal (300 ml)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mankai beverage
Description: Recommended background healthy diet with Mankai supplementation after main meal (300 ml)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water (control)
Description: Recommended background healthy diet with water supplementation after main meal (300 ml)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water (control)
Description: Recommended background healthy diet with water supplementation after main meal (300 ml)
Study: NCT04187170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength physical training
Description: progressive high-load strength training over 6 months, consisting in repeated physical exercises to increase the muscular mass and force by altering concentric and eccentric muscle contractions against high resistance.
Study: NCT05506319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: The patients will be randomized for the initial suspension of norepinephrine (norepinephrine group).~Interruption means suspension for at least 24 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: The patients will be randomized for the initial suspension of vasopressin (vasopressin group).~Interruption means suspension for at least 24 hours.
Study: NCT04405180

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Oral placebo capsule at a dose of 20 mg administered three times per day, during the day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20mg sodium nitrite tid
Description: Oral, inorganic sodium nitrite capsule at a dose of 20 mg administered three times per day, during the day.
Study: NCT04996654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergame
Description: According to the training concept, each participant is instructed to train 5x/week for 21 min per session resulting in a weekly exercise volume of 105 min. All training sessions are planned to take place at participant's homes using the exergame training system Dividat Senso (Dividat AG, Schindellegi, Switzerland; CE certification).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: An active control group will proceed with usual care as provided by the memory clinics where the patients are recruited.
Study: NCT04699682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: During follow-up visits, as part of this research, additional stool samples are taken every month (M1 to M12).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BHR Case
Description: During follow-up visits, compared to the usual management of patients with BHRe (monthly sampling for 6 consecutive months), additional samples are taken as described below:~- stool samples taken at different times:~* every 7 days during the first month (M1)~* every 14 days for the following months until the end of the patient's participation (M2 to M12).
Study: NCT06250023

Intervention type: OTHER
Intervention: Early shift til oral antibiotic treatment for osteomyelitis
Description: To investigate whether early transition to oral AB treatment after one week of IV treatment is non-inferior to the current national guideline of continued IV AB treatment for two to four weeks followed by oral AB treatment for PVO.
Study: NCT06145360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: the impact of incorporating Empagliflozin, an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor, into the existing therapeutic regimen of Insulin+Metformin+DPP4 inhibitor (DPP4I) in poorly controlled type 2 diabetes mellitus (T2DM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin+Metformin+DPP4 inhibitor (DPP4I)
Description: Group B: usual care group but without Empagliflozin with adjustment of therapy as the standard of care